The significance of autoantibody changes over time in primary biliary cirrhosis

Michele M. Tana, Zakera Shums, Jay Milo, Gary L. Norman, Patrick S Leung, M. Eric Gershwin, Mazen Noureddin, David E. Kleiner, Xiongce Zhao, Theo Heller, Jay H. Hoofnagle

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: In primary biliary cirrhosis (PBC), the antimitochondrial antibody is a cornerstone of diagnosis, but there have been conflicting reports about the correlation of autoantibodies with disease stage and prognosis. We studied whether autoantibody levels changed over time and sought correlations with clinical outcomes in a cohort of patients with PBC. Methods: We tested serial serum samples from patients with PBC at a research institution for several autoantibodies. Long-term clinical follow-up data were used to calculate the slopes (change over time) for autoantibodies, platelet count, Ishak fibrosis score, biopsy copper, and number of portal areas with bile ducts. An adverse clinical outcome was defined as hepatic decompensation, development of hepatocellular carcinoma, liver transplantation, or liver-related death. We performed linear or logistic regression or Fisher exact test as appropriate, adjusting for multiple comparisons. Results: Twenty-seven patients with PBC with 145 serum samples were studied. Of the cohort, 85% was white, 81% was female, and median follow-up time was 20 years. Of the autoantibodies tested, only sp100 changed significantly over time. The sp100 slope was inversely associated with the Ishak fibrosis slope (parameter estimate, -0.05; P = .0003). Conclusions: While changes in most autoantibodies over time do not seem to correlate with clinical outcomes in PBC, a change in the sp100 autoantibody level may have prognostic utility with respect to the development of fibrosis on liver biopsy.

Original languageEnglish (US)
Pages (from-to)601-606
Number of pages6
JournalAmerican Journal of Clinical Pathology
Volume144
Issue number4
DOIs
StatePublished - Oct 1 2015

Fingerprint

Biliary Liver Cirrhosis
Autoantibodies
Fibrosis
Biopsy
Liver
Bile Ducts
Serum
Platelet Count
Liver Cirrhosis
Liver Transplantation
Copper
Hepatocellular Carcinoma
Linear Models
Logistic Models
Antibodies
Research

Keywords

  • Autoantibodies
  • Autoimmune liver disease
  • Primary biliary cirrhosis
  • Prognosis
  • Serum markers
  • Ursodiol

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The significance of autoantibody changes over time in primary biliary cirrhosis. / Tana, Michele M.; Shums, Zakera; Milo, Jay; Norman, Gary L.; Leung, Patrick S; Gershwin, M. Eric; Noureddin, Mazen; Kleiner, David E.; Zhao, Xiongce; Heller, Theo; Hoofnagle, Jay H.

In: American Journal of Clinical Pathology, Vol. 144, No. 4, 01.10.2015, p. 601-606.

Research output: Contribution to journalArticle

Tana, MM, Shums, Z, Milo, J, Norman, GL, Leung, PS, Gershwin, ME, Noureddin, M, Kleiner, DE, Zhao, X, Heller, T & Hoofnagle, JH 2015, 'The significance of autoantibody changes over time in primary biliary cirrhosis', American Journal of Clinical Pathology, vol. 144, no. 4, pp. 601-606. https://doi.org/10.1309/AJCPQV4A7QAEEFEV
Tana, Michele M. ; Shums, Zakera ; Milo, Jay ; Norman, Gary L. ; Leung, Patrick S ; Gershwin, M. Eric ; Noureddin, Mazen ; Kleiner, David E. ; Zhao, Xiongce ; Heller, Theo ; Hoofnagle, Jay H. / The significance of autoantibody changes over time in primary biliary cirrhosis. In: American Journal of Clinical Pathology. 2015 ; Vol. 144, No. 4. pp. 601-606.
@article{07aba24eecd14fc7bfd06dd99c68162a,
title = "The significance of autoantibody changes over time in primary biliary cirrhosis",
abstract = "Objectives: In primary biliary cirrhosis (PBC), the antimitochondrial antibody is a cornerstone of diagnosis, but there have been conflicting reports about the correlation of autoantibodies with disease stage and prognosis. We studied whether autoantibody levels changed over time and sought correlations with clinical outcomes in a cohort of patients with PBC. Methods: We tested serial serum samples from patients with PBC at a research institution for several autoantibodies. Long-term clinical follow-up data were used to calculate the slopes (change over time) for autoantibodies, platelet count, Ishak fibrosis score, biopsy copper, and number of portal areas with bile ducts. An adverse clinical outcome was defined as hepatic decompensation, development of hepatocellular carcinoma, liver transplantation, or liver-related death. We performed linear or logistic regression or Fisher exact test as appropriate, adjusting for multiple comparisons. Results: Twenty-seven patients with PBC with 145 serum samples were studied. Of the cohort, 85{\%} was white, 81{\%} was female, and median follow-up time was 20 years. Of the autoantibodies tested, only sp100 changed significantly over time. The sp100 slope was inversely associated with the Ishak fibrosis slope (parameter estimate, -0.05; P = .0003). Conclusions: While changes in most autoantibodies over time do not seem to correlate with clinical outcomes in PBC, a change in the sp100 autoantibody level may have prognostic utility with respect to the development of fibrosis on liver biopsy.",
keywords = "Autoantibodies, Autoimmune liver disease, Primary biliary cirrhosis, Prognosis, Serum markers, Ursodiol",
author = "Tana, {Michele M.} and Zakera Shums and Jay Milo and Norman, {Gary L.} and Leung, {Patrick S} and Gershwin, {M. Eric} and Mazen Noureddin and Kleiner, {David E.} and Xiongce Zhao and Theo Heller and Hoofnagle, {Jay H.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1309/AJCPQV4A7QAEEFEV",
language = "English (US)",
volume = "144",
pages = "601--606",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "4",

}

TY - JOUR

T1 - The significance of autoantibody changes over time in primary biliary cirrhosis

AU - Tana, Michele M.

AU - Shums, Zakera

AU - Milo, Jay

AU - Norman, Gary L.

AU - Leung, Patrick S

AU - Gershwin, M. Eric

AU - Noureddin, Mazen

AU - Kleiner, David E.

AU - Zhao, Xiongce

AU - Heller, Theo

AU - Hoofnagle, Jay H.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Objectives: In primary biliary cirrhosis (PBC), the antimitochondrial antibody is a cornerstone of diagnosis, but there have been conflicting reports about the correlation of autoantibodies with disease stage and prognosis. We studied whether autoantibody levels changed over time and sought correlations with clinical outcomes in a cohort of patients with PBC. Methods: We tested serial serum samples from patients with PBC at a research institution for several autoantibodies. Long-term clinical follow-up data were used to calculate the slopes (change over time) for autoantibodies, platelet count, Ishak fibrosis score, biopsy copper, and number of portal areas with bile ducts. An adverse clinical outcome was defined as hepatic decompensation, development of hepatocellular carcinoma, liver transplantation, or liver-related death. We performed linear or logistic regression or Fisher exact test as appropriate, adjusting for multiple comparisons. Results: Twenty-seven patients with PBC with 145 serum samples were studied. Of the cohort, 85% was white, 81% was female, and median follow-up time was 20 years. Of the autoantibodies tested, only sp100 changed significantly over time. The sp100 slope was inversely associated with the Ishak fibrosis slope (parameter estimate, -0.05; P = .0003). Conclusions: While changes in most autoantibodies over time do not seem to correlate with clinical outcomes in PBC, a change in the sp100 autoantibody level may have prognostic utility with respect to the development of fibrosis on liver biopsy.

AB - Objectives: In primary biliary cirrhosis (PBC), the antimitochondrial antibody is a cornerstone of diagnosis, but there have been conflicting reports about the correlation of autoantibodies with disease stage and prognosis. We studied whether autoantibody levels changed over time and sought correlations with clinical outcomes in a cohort of patients with PBC. Methods: We tested serial serum samples from patients with PBC at a research institution for several autoantibodies. Long-term clinical follow-up data were used to calculate the slopes (change over time) for autoantibodies, platelet count, Ishak fibrosis score, biopsy copper, and number of portal areas with bile ducts. An adverse clinical outcome was defined as hepatic decompensation, development of hepatocellular carcinoma, liver transplantation, or liver-related death. We performed linear or logistic regression or Fisher exact test as appropriate, adjusting for multiple comparisons. Results: Twenty-seven patients with PBC with 145 serum samples were studied. Of the cohort, 85% was white, 81% was female, and median follow-up time was 20 years. Of the autoantibodies tested, only sp100 changed significantly over time. The sp100 slope was inversely associated with the Ishak fibrosis slope (parameter estimate, -0.05; P = .0003). Conclusions: While changes in most autoantibodies over time do not seem to correlate with clinical outcomes in PBC, a change in the sp100 autoantibody level may have prognostic utility with respect to the development of fibrosis on liver biopsy.

KW - Autoantibodies

KW - Autoimmune liver disease

KW - Primary biliary cirrhosis

KW - Prognosis

KW - Serum markers

KW - Ursodiol

UR - http://www.scopus.com/inward/record.url?scp=84947742138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947742138&partnerID=8YFLogxK

U2 - 10.1309/AJCPQV4A7QAEEFEV

DO - 10.1309/AJCPQV4A7QAEEFEV

M3 - Article

VL - 144

SP - 601

EP - 606

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 4

ER -